JP2014507442A - 心臓線維芽細胞の心筋細胞への再プログラム化による心臓修復 - Google Patents

心臓線維芽細胞の心筋細胞への再プログラム化による心臓修復 Download PDF

Info

Publication number
JP2014507442A
JP2014507442A JP2013555521A JP2013555521A JP2014507442A JP 2014507442 A JP2014507442 A JP 2014507442A JP 2013555521 A JP2013555521 A JP 2013555521A JP 2013555521 A JP2013555521 A JP 2013555521A JP 2014507442 A JP2014507442 A JP 2014507442A
Authority
JP
Japan
Prior art keywords
expression cassette
tbx5
mef2c
subject
hand2
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2013555521A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014507442A5 (enExample
Inventor
ヨン‐ジェ ナム
クンフア ソン
エリック オルソン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Texas System
Original Assignee
University of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Texas System filed Critical University of Texas System
Publication of JP2014507442A publication Critical patent/JP2014507442A/ja
Publication of JP2014507442A5 publication Critical patent/JP2014507442A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0657—Cardiomyocytes; Heart cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/00041—Use of virus, viral particle or viral elements as a vector
    • C12N2770/00043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2013555521A 2011-02-22 2012-02-22 心臓線維芽細胞の心筋細胞への再プログラム化による心臓修復 Pending JP2014507442A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161445390P 2011-02-22 2011-02-22
US61/445,390 2011-02-22
PCT/US2012/026113 WO2012116064A1 (en) 2011-02-22 2012-02-22 Cardiac repair by reprogramming of cardiac fibroblasts into cardiomyocytes

Publications (2)

Publication Number Publication Date
JP2014507442A true JP2014507442A (ja) 2014-03-27
JP2014507442A5 JP2014507442A5 (enExample) 2015-04-16

Family

ID=45922797

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013555521A Pending JP2014507442A (ja) 2011-02-22 2012-02-22 心臓線維芽細胞の心筋細胞への再プログラム化による心臓修復

Country Status (6)

Country Link
US (2) US9017661B2 (enExample)
EP (1) EP2678354A1 (enExample)
JP (1) JP2014507442A (enExample)
AU (1) AU2012220702B2 (enExample)
CA (1) CA2827329A1 (enExample)
WO (1) WO2012116064A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015213441A (ja) * 2014-05-08 2015-12-03 学校法人慶應義塾 心筋様細胞の作製方法及びそれに用いる培地
JP2020524518A (ja) * 2017-06-21 2020-08-20 モグリファイ リミテッド 心筋細胞への細胞リプログラミング

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6236393B2 (ja) * 2011-11-09 2017-11-22 セダーズ−シナイ メディカル センター 転写因子に基づくペースメーカー細胞の生成およびその使用方法
EP3060237B1 (en) * 2013-10-25 2021-08-18 Wayne State University Modified reprogramming protein for use in treating a cancer
EP3177302A4 (en) * 2014-08-07 2018-04-11 Duke University Compositions and methods for the reprogramming of cells into cardiomyocytes
KR101530278B1 (ko) * 2014-09-04 2015-06-24 부산대학교 산학협력단 심근전환유전자 및 심혈관재생유전자를 포함하는 아데노부속바이러스를 유효성분으로 포함하는, 허혈성 심장질환 예방 또는 치료용 조성물
US9885018B1 (en) * 2015-03-16 2018-02-06 The Regents Of The University Of Colorado, A Body Corporate High efficiency reprogramming of fibroblasts into cardiomyocytes
US20210180023A1 (en) * 2017-08-15 2021-06-17 The Board Of Regents Of The University Of Texas System Cardiac repair by reprogramming of adult cardiac fibroblasts into cardiomyocytes
US12042525B2 (en) 2018-01-05 2024-07-23 University Of Houston System Serum response factor regenerates senescent cells
GB2571704A (en) * 2018-02-22 2019-09-11 Georg August Univ Gottingen Stiftung Offentlichen Rechts Univer Sitatsmedzin Goettingen Prevention or treatment of cardiac arrhytmia and sudden cardiac death
AU2019333315B2 (en) 2018-08-30 2022-09-29 Tenaya Therapeutics, Inc. Cardiac cell reprogramming with myocardin and ASCL1

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010075575A1 (en) * 2008-12-23 2010-07-01 Biopips, Inc. Compositions and methods for re-programming cells without genetic modification
WO2011139688A2 (en) * 2010-04-28 2011-11-10 The J. David Gladstone Institutes Methods for generating cardiomyocytes
WO2011163531A2 (en) * 2010-06-23 2011-12-29 Vivoscript, Inc. Compositions and methods for re-programming cells without genetic modification for treatment of cardiovascular diseases

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0273085A1 (en) 1986-12-29 1988-07-06 IntraCel Corporation A method for internalizing nucleic acids into eukaryotic cells
WO1999062940A2 (en) 1998-05-30 1999-12-09 Collateral Therapeutics, Inc. Methods of altering cardiac cell phenotype
AU2002216751A1 (en) * 2000-06-30 2002-01-14 Collateral Therapeutics, Inc. Dual recombinant gene therapy compositions and methods of use
WO2007056759A2 (en) * 2005-11-08 2007-05-18 University Of South Florida Improved method of stem cell therapy for cardiovascular repair
US20100172883A1 (en) * 2007-01-19 2010-07-08 Bruneau Benoit Gaetan Methods of generating cardiomyocytes
WO2009145761A1 (en) * 2008-05-27 2009-12-03 Mayo Foundation For Medical Education And Research Methods and materials for using cells to treat heart tissue

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010075575A1 (en) * 2008-12-23 2010-07-01 Biopips, Inc. Compositions and methods for re-programming cells without genetic modification
WO2011139688A2 (en) * 2010-04-28 2011-11-10 The J. David Gladstone Institutes Methods for generating cardiomyocytes
WO2011163531A2 (en) * 2010-06-23 2011-12-29 Vivoscript, Inc. Compositions and methods for re-programming cells without genetic modification for treatment of cardiovascular diseases

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JPN6016002883; Ｃｅｌｌ Ｖｏｌ．１４２，　Ｎｏ．３, 2010, ｐ．３７５-３８６ *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015213441A (ja) * 2014-05-08 2015-12-03 学校法人慶應義塾 心筋様細胞の作製方法及びそれに用いる培地
JP2020524518A (ja) * 2017-06-21 2020-08-20 モグリファイ リミテッド 心筋細胞への細胞リプログラミング

Also Published As

Publication number Publication date
US20150307847A1 (en) 2015-10-29
AU2012220702A1 (en) 2013-08-22
WO2012116064A1 (en) 2012-08-30
US9523079B2 (en) 2016-12-20
EP2678354A1 (en) 2014-01-01
AU2012220702B2 (en) 2016-12-15
US9017661B2 (en) 2015-04-28
CA2827329A1 (en) 2012-08-30
US20120213738A1 (en) 2012-08-23

Similar Documents

Publication Publication Date Title
US9523079B2 (en) Cardiac repair by reprogramming of cardiac fibroblasts into cardiomyocytes
US20200190511A1 (en) Micro-rna family that modulates fibrosis and uses thereof
US20050182011A1 (en) Inhibition of TRP channels as a treatment for cardiac hypertrophy and heart failure
US10300147B2 (en) Therapeutic miRNAs for treating heart and skeletal muscle diseases
US20250018009A1 (en) Serum response factor regenerates senescent cells
JP2012500199A (ja) 血管統合性を促進するマイクロ−ｒｎａおよびその使用
WO2019036086A1 (en) CARDIAC REPAIR BY REPROGRAMMING CARDIAC FIBROBLASTS ADULT TO CARDIOMYOCYTES
CN105030808B (zh) 调控纤维化的微小rna家族及其用途
WO2007131113A2 (en) Modulation of calmodulin- binding transcription activator (camta) as a treatment for cardiac hypertrophy, heart failure, and heart injury
US10772974B2 (en) Compositions and methods for cardiac regeneration
US20050265999A1 (en) Modulation of 5-HT2 receptors as a treatment for cardiovascular diseases
US20090220507A1 (en) Inhibition of extracellular signal-regulated kinase 1/2 as a treatment for cardiac hypertrophy and heart failure
US20050283841A1 (en) Inhibition of protein kinase C-related kinase (PRK) as a treatment for cardiac hypertrophy and heart failure
US20080031818A1 (en) Use of Modulators of a Novel Form of Muscle Selective Calcineurin Interacting Protein (Mcip-1-38) as a Treatment for Cardiovascular Diseases
WO2023077052A1 (en) Reprogramming of adult cardiac fibroblasts into cardiomyocytes using phf7
US20060110390A1 (en) Inhibition of Ku as a treatment for cardiovascular diseases

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150223

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150223

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20150520

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160128

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160419

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160726

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20161024